Christina Maria Flies

Christina Maria Flies

Auto-generated profile, based on publicly available information

Christina Maria Flies

From the Department of Neurology and Neurosurgery (C.M.F., T.J.S., B.I.d.L., B.J.P.K., P.A.R.), UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
CFChristina Maria Flies
Christina Maria Flies
MFMichel Friedrich
Michel Friedrich
PLPhilipp Lohmann
Philipp Lohmann
KGKarin Alida van Garderen
Karin Alida van Garderen
MSMarion Smits
Marion Smits
TSTom J. Snijders
Tom J. Snijders
Radiological progression may originate from progressive disease (PD) or pseudoprogression/treatment-associated changes. We assessed radiological progression in O6-methylguanine-DNA methyltransferase (MGMT) promoter-methylated glioblastoma treated with standard-of-care chemoradiotherapy with or without the integrin inhibitor cilengitide according to the modified response assessment in neuro-oncology (RANO) criteria of 2017. Patients with ≥ 3 follow-up MRIs were included. Preliminary PD was defined as a ≥ 25% increase of the sum of products of perpendicular diameters (SPD) of a new or increasing lesion compared to baseline. PD required a second ≥25% increase of the SPD. Treatment-associated changes require stable or regressing disease after preliminary PD. Of the 424 evaluable patients, 221 patients (52%) were randomized into the cilengitide and 203 patients (48%) into the control arm. After chemoradiation with or without cilengitide, preliminary PD occurred in 274 patients (65%) during available follow-up, and 88 of these patients (32%) had treatment-associated changes, whereas 67 patients (25%) had PD. The remaining 119 patients (43%) had no further follow-up after preliminary PD. Treatment-associated changes were more common in the cilengitide arm than in the standard-of-care arm (24% vs. 17%; relative risk, 1.3; 95% CI, 1.004–1.795; P = .047). Treatment-associated changes occurred mainly during the first 6 months after RT (54% after 3 months vs. 13% after 6 months). With the modified RANO criteria, the rate of treatment-associated changes was low compared to previous studies in MGMT promoter-methylated glioblastoma. This rate was higher after cilengitide compared to standard-of-care treatment. Confirmatory scans, as recommended in the modified RANO criteria, were not always available reflecting current clinical practice.

11 June 2021 in Neuroradiology
Verified
Journal Article
Open access
PDF file
CFChristina M. Flies
Christina M. Flies
TSTom J. Snijders
Tom J. Snijders
TSTom Van Seeters
Tom Van Seeters
MSMarion Smits
Marion Smits
FVFilip Yves De Vos
Filip Yves De Vos
JDJan Willem Dankbaar
Jan Willem Dankbaar
Purpose: Predicting malignant progression of grade II gliomas would allow for earlier initiation of treatment. The hypothesis for this single-centre, case–control study was that the perfusion signal on ASL-MRI predicts such malignant progression in the following 12 months. Methods: Consecutive patients with the following criteria were included: ≥ 18 years, grade II glioma (biopsied or resected) and an ASL-MRI 6–12 months prior to malignant progression (cases) or stable disease (controls). Malignant progression was defined either radiologically (new T1w-contrast enhancement) or histologically (neurosurgical tissue sampling). Three controls were matched with each case. Some patients served as their own control by using earlier imaging. The ASL-MRIs were reviewed by two neuroradiologists and classified as positive (hyper-intense or iso-intense compared to cortical grey matter) or negative (hypo-intense). In patients with epilepsy, a neurologist reviewed clinicoradiological data to exclude peri-ictal pseudoprogression. The statistical analysis included diagnostic test properties, a Cohen’s Kappa interrater reliability coefficient and stratification for previous radiotherapy. Results: Eleven cases (median age = 48, IQR = 43–50 years) and 33 controls (43, 27–50 years) were included. Malignant progression appeared at 37 months (median, IQR = 17–44) after first surgery. Thirty ASL-MRIs were assessed as negative and 14 as positive. None of the MRIs showed signs of peri-ictal pseudoprogression. ASL significantly predicted subsequent malignant progression (sensitivity = 73%; specificity = 82%; OR = 12; 95%-CI = 2.4–59.1; p = 0.002). The interrater reliability coefficient was 0.65. In stratified analysis, ASL-MRI predicted malignant progression both in patients with previous radiotherapy and in those without (Mantel–Haenszel test, p = 0.003). Conclusion: Perfusion imaging with ASL-MRI can predict malignant progression within 12 months in patients with grade II glioma.

18 April 2022 in Neurology
Verified
Journal Article
Open access
PDF file
CFChristina M. Flies
Christina M. Flies
KLKarlijn H. van Leuken
Karlijn H. van Leuken
MVMarlies Ten Voorde
Marlies Ten Voorde
JVJoost J.C. Verhoeff
Joost J.C. Verhoeff
FVFilip Yves De Vos
Filip Yves De Vos
TSTom J. Snijders
Tom J. Snijders
Background and Objectives Posttreatment radiologic deterioration of an irradiated high-grade (WHO grade 3–4) glioma (HGG) may be the result of true progressive disease or treatment-induced effects (TIE). Differentiation between these entities is of great importance but remains a diagnostic challenge. This study assesses the diagnostic value of conventional MRI characteristics to differentiate progressive disease from TIE in HGGs. Methods In this single-center, retrospective, consecutive cohort study, we included adults with a HGG who were treated with (chemo-)radiotherapy and subsequently developed a new or increasing contrast-enhancing lesion on conventional follow-up MRI. TIE and progressive disease were defined radiologically as stable/decreased for ≥6 weeks or Response Assessment in Neuro-Oncology progression and histologically as TIE without viable tumor or progressive disease. Two neuroradiologists assessed 21 preselected MRI characteristics of the progressive lesions. The statistical analysis included logistic regression to develop a full multivariable model, a diagnostic model with model reduction, and a Cohen kappa interrater reliability (IRR) coefficient. Results A total of 210 patients (median age 61 years, interquartile range 54–68, 189 male) with 284 lesions were included, of whom 141 (50%) had progressive disease. Median time to progressive disease was 2 (0.7–6.1) and to TIE 0.9 (0.7–3.5) months after radiotherapy. After multivariable modeling and model reduction, the following determinants prevailed: radiation dose (odds ratio [OR] 0.68, 95% CI 0.49–0.93), longer time to progression (TTP; OR 3.56, 95% CI 1.84–6.88), marginal enhancement (OR 2.04, 95% CI 1.09–3.83), soap bubble enhancement (OR 2.63, 95% CI 1.39–4.98), and isointense apparent diffusion coefficient (ADC) signal (OR 2.11, 95% CI 1.05–4.24). ORs >1 indicate higher odds of progressive disease. The Hosmer & Lemeshow test showed good calibration (p = 0.947) and the area under the receiver operating characteristic curve was 0.722 (95% CI 0.66–0.78). In the glioblastoma subgroup, TTP, marginal enhancement, and ADC signal were significant. IRR analysis between neuroradiologists revealed moderate to near perfect agreement for the predictive items but poor agreement for others. Discussion Several characteristics from conventional MRI are significant predictors for the discrimination between progressive disease and TIE. However, IRR was variable. Conventional MRI characteristics from this study should be incorporated into a multimodal diagnostic model with advanced imaging techniques. Classification of Evidence This study provides Class II evidence that in patients with irradiated HGGs, radiation dose, longer TTP, marginal enhancement, soap bubble enhancement, and isointense ADC signal distinguish progressive disease from TIE.

13 June 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
CFChristina Maria Flies
Christina Maria Flies
TSTom J. Snijders
Tom J. Snijders
BLBeverly Iendra De Leeuw
Beverly Iendra De Leeuw
EMEmiel Alexander van Maren
Emiel Alexander van Maren
BKBart Jean Pieter Kersten
Bart Jean Pieter Kersten
JDJan Willem Dankbaar
Jan Willem Dankbaar
BACKGROUND AND PURPOSE: Treatment-induced effects are difficult to differentiate from progressive disease in radiologically progressing diffuse gliomas after treatment. This retrospective, single-center cohort study investigated the diagnostic value of arterial spin-labeling perfusion in differentiating progressive disease from treatment-induced effects in irradiated patients with a high-grade glioma. MATERIALS AND METHODS: Adults with a high-grade glioma diagnosed between January 1, 2012, and December 31, 2018, with a new or increasing contrast-enhancing lesion after radiotherapy with or without chemotherapy and arterial spin-labeling were consecutively included. Arterial spin-labeling is part of the routine follow-up examinations of patients with a high-grade glioma. The outcomes of progressive disease or treatment-induced effects were defined after histologic or >6 weeks radiologic follow-up. Two neuroradiologists graded the arterial spin-labeling visually as negative (hypointense to gray matter) or positive (iso-/hyperintense). Additionally, the arterial spin-labeling signal intensity in the enhancing lesion was compared quantitatively with that in the contralateral normal brain. Diagnostic test properties and the Cohen κ inter- and intrarater reliability were determined. We present data according to the time after radiation therapy. RESULTS: We included 141 patients with 173 lesions (median age, 63 years). Ninety-four (54%) lesions showed treatment-induced effects, and 79 (46%), progressive disease. For visual analysis, the ORs of an arterial spin-labeling positive for progressive disease in the group with progression within 3, between 3 and 6, and after 6 months after radiation therapy were 0.65 (95% CI, 0.28–1.51; P = .319), 3.5 (95% CI, 0.69–17.89; P = .132), and 6.8 (95% CI, 1.48–32; P = .014). The areas under the curve were 0.456, 0.652, and 0.719. In quantitative analysis, the areas under the curve were 0.520, 0.588, and 0.587 in these groups. Inter- and intrarater reliability coefficients were 0.67 and 0.62. CONCLUSIONS: Arterial spin-labeling performed poorly in differentiating progressive disease from treatment-induced effects in high-grade gliomas within 6 months after radiation therapy, with fair performance after this period. Arterial spin-labeling may need to be combined with other imaging features and clinical information for better performance.